A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 1577
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : CAR
Long Form : chimeric antigen receptor
No. Year Title Co-occurring Abbreviation
2020 'Off-the-shelf' allogeneic CAR T cells: development and challenges. ---
2020 3D Nanochannel Electroporation for Macromolecular Nucleotide Delivery. 3D NEP, NK
2020 A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy. CDH
2020 A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat Cells. ABD
2020 A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts. ---
2020 AAVS1 site-specific integration of the CAR gene into human primary T cells using a linear closed-ended AAV-based DNA vector. AAV
2020 Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery. AKI, CRS, ICANS, KDIGO
2020 Adeno-Associated Viral Vectors for Homology-Directed Generation of CAR-T Cells. ---
2020 Advanced Cell Mapping Visualizations for Single Cell Functional Proteomics Enabling Patient Stratification. PSI, t-SNE, UMAP
10  2020 Advances and Challenges of CAR T Cells in Clinical Trials. ---
11  2020 Advances in pediatric psychooncology. ---
12  2020 Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma. cHL, HL, R/R
13  2020 Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment. FDA
14  2020 All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy. ---
15  2020 Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma. ---
16  2020 An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. CLDN6
17  2020 Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? BCMA, MM
18  2020 Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. BCMA, FHVH, scFv
19  2020 Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib. liso-cel
20  2020 Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy. ---
21  2020 Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies. ---
22  2020 Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. CRS
23  2020 Autologous CAR T-cell therapies supply chain: challenges and opportunities? ---
24  2020 Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist. AEs
25  2020 B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. BCMA, MM
26  2020 B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models. scFv
27  2020 Bi-specific and Split CAR T Cells Targeting CD13 and TIM3 Eradicate Acute Myeloid Leukemia. AML, Nbs, STAR
28  2020 CAR T cells and checkpoint inhibition for the treatment of glioblastoma. GBM
29  2020 CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies. TGF-beta
30  2020 CAR T-cell product performance in haematological malignancies before and after marketing authorisation. ---
31  2020 CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress. ---
32  2020 CAR T-Cell-Associated Neurotoxicity: Current Management and Emerging Treatment Strategies. CRS, ICANS
33  2020 CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia. B-ALL, CD
34  2020 CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. BCMA, MM
35  2020 Cell penetrating peptide functionalized perfluorocarbon nanoemulsions for targeted cell labeling and enhanced fluorine-19 MRI detection. PFC, TAT
36  2020 Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer. CARs, PCa
37  2020 Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications. CAR-T, FAP, HER2, IGF-1R, IL-11RA, ROR1, SAA, scFv, TAA
38  2020 Chimeric Antigen Receptor T Cell Therapy: A Novel Modality for Immune Modulation. PD
39  2020 Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment. ---
40  2020 Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer. ---
41  2020 Chimeric antigen receptor T-cell therapy for multiple myeloma. ---
42  2020 Chimeric antigen receptor T-cell therapy: design improvements and therapeutic strategies in cancer treatment. ---
43  2020 Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. ALL, BCMA, CLL, MM, NHL
44  2020 Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions. ---
45  2020 Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. IPs, scRNA-seq
46  2020 Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. ASTCT, axi-cel, B-ALL, CRS, DLBCL, ICANS
47  2020 Correlation of IL-6 secretion and hyponatremia with the use of CD19+ chimeric antigen receptor T-cells
. ALL, AVP, IL-6, IQR
48  2020 Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma. ALL, ASCT, DLBCL, FDA, MM, PIs, RRMM
49  2020 Current challenges and emerging opportunities of CAR-T cell therapies. ACT, FDA
50  2020 Current Status of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma. MM
51  2020 CXCR1 Expression to Improve Anti-Cancer Efficacy of Intravenously Injected CAR-NK Cells in Mice with Peritoneal Xenografts. NK
52  2020 CXCR2-modified CAR-Tcells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. ---
53  2020 Determination of Cytotoxic Potential of CAR-T Cells in Co-cultivation Assays. ---
54  2020 Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model. PBPK, PK-PD, TGI
55  2020 Donor-specific chimeric antigen receptor Tregs limit rejection in naive but not sensitized allograft recipients. DSAs
56  2020 Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. CRS, GI
57  2020 Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor scFv
58  2020 Enhancing Chimeric Antigen Receptor T cell Efficacy in Solid Tumors. ---
59  2020 Feasibility of real-time in vivo 89Zr-DFO-labeled CAR T-cell trafficking using PET imaging. hPBMC, PET
60  2020 Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies. BiTEs
61  2020 Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. CRS, GSDME
62  2020 Generation of Chimeric Antigen Receptor T Cells Using Gammaretroviral Vectors. ---
63  2020 Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. GPC3-CAR, HCC
64  2020 Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond. ALL, AML
65  2020 Humanized mice are precious tools for evaluation of hematopoietic gene therapies and preclinical modeling to move towards a clinical trial. HSCs
66  2020 Identification of Cell Surface Targets for CAR T Cell Immunotherapy. ---
67  2020 IL6 Induces an IL22+ CD8+ T-cell Subset with Potent Antitumor Function. TCR, TIL
68  2020 Imaging CAR T Cell Trafficking with eDHFR as a PET Reporter Gene. CT, eDHFR, PET, Rluc, TMP, YFP
69  2020 Imaging Chimeric Antigen Receptor (CAR) Activation. ---
70  2020 Implications of T cell receptor biology on the development of new T cell therapies for cancer. TCR
71  2020 Improved anti-tumor efficacy of chimeric antigen receptor T cells that secrete single-domain antibody fragments. ---
72  2020 In Vitro-Transcribed (IVT)-mRNA CAR Therapy Development. ---
73  2020 Inclusion of Dap10 or 4-1BB costimulation domains in the chPD1 receptor enhances anti-tumor efficacy of T cells in murine models of lymphoma and melanoma. chPD1
74  2020 Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma. CAIX, PP2A
75  2020 Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. ---
76  2020 Interleukin-23 engineering improves CAR T cell function in solid tumors. IL, TCR
77  2020 Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering. LNPs, mRNA
78  2020 Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia? AML, HSPC, mAbs
79  2020 Joint profiling of chromatin accessibility and CAR-T integration site analysis at population and single-cell levels. ---
80  2020 Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). EBMT, JACIE
81  2020 Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. CRS
82  2020 Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data. CARRGO
83  2020 MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma. ANNT, HNSCC
84  2020 Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies. ---
85  2020 Myeloid cell-targeted miR-146a mimic inhibits NF-kappaB-driven inflammation and leukemia progression in vivo. ---
86  2020 Natural Killer Cells: Diverse Functions in Tumor Immunity and Defects in Pre-neoplastic and Neoplastic Stages of Tumorigenesis. ADCC, IFN, NK, TNF
87  2020 New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances. ALL, BiTE, CRISPR
88  2020 Next Generation of Adoptive T Cell Therapy Using CRISPR/Cas9 Technology: Universal or Boosted? ACT, TCR
89  2020 Nitinol thin films functionalized with CAR-T cells for the treatment of solid tumours. ---
90  2020 Oncolytic adenovirus targeting TGF-beta enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer. IL
91  2020 Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials. B-ALL, DLBCL
92  2020 Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy. PROMIS
93  2020 PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. ---
94  2020 Platforms for Clinical-Grade CAR-T Cell Expansion. ---
95  2020 Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy. ---
96  2020 Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma. BCMA
97  2020 Production of Lentivirus for the Establishment of CAR-T Cells. ---
98  2020 PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours. ---
99  2020 Rapid and Effective Generation of Nanobody Based CARs using PCR and Gibson Assembly. CD, EMA, FDA, scFvs
100  2020 Rapid Transduction and Expansion of Transduced T Cells with Maintenance of Central Memory Populations. PBMCs